The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma
Shivaram S, Yan H, Tang H, Anderson H, Kaddoura M, Wiedmeier-Nutor J, Tian S, Howe M, Bolarinwa A, Zepeda Mendoza C, Gupta V, Lehman S, Mitsiades C, Bergsagel P, Braggio E, Boise L, Fonseca R, Maura F, Kumar S, Baughn L. The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma. Blood 2024, 144: 4635-4635. DOI: 10.1182/blood-2024-205385.Peer-Reviewed Original ResearchMayo Clinic cohortNoxa proteinMultiple myelomaG alleleIncreased expressionGene expressionCyclin D1Clinical cohortExpression of CCND1Cell linesAllele specific effectsBCL-2 inhibitor venetoclaxLevels of NoxaHistone mark H3K27acG risk allelePrimary cytogenetic abnormalityPlasma cell malignancyAssociated with increased expressionRNA sequencing dataHuman myeloma cell linesKO cell linesWestern blottingAnalyzed whole-exomeChIP-seqWhole genome